The Surfers spend the final day of AASLD 2020 looking at two very different sets of issues.
Issue 1: challenges proving efficacy in F2 populations, particularly in terms of fibrosis.
Issue 2: social burdens of poor dietary choices around the world, particularly given how developing PNAFLD (pediatric non-alcoholic fatty liver disease) can create a metabolic burden that can last a lifetime.
In the end, the group remained optimistic about the explosion of knowledge around drugs and diagnostics for NASH and NAFLD but troubled by the lack of social policy, awareness or education around these issues.
Dr. Stephen Harrison — LP23
RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE3 WEEK 72 ITNERIM SURROGATE EFFICACY ANALYSIS
Louise Campbell MSc AP — 141
DIET RELATED MORTALITYARY AMONG NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): DATA FROM THE GLOBAL BURDEN OF DISEASE (GBD) 2017
Roger Green —
L03 – ALDAFERMIN (NGM282) PRODUCES GREATER ANTI-FIBROTIC RESPONSE IN PATIENTS WITH NONALCOHOLIC STREATOHEPATITIS AND ADVANCED FIBROSIS
&
0143
ONSET OF OBESITY-RELATED PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE (PNAFLD) DURING PREPUBERTAL GROWTH EXACERBATES HEPATIC INFLAMMATION AND MITOCHONDRIAL DNA DEPLETION TO ACCELERATE LIVER INJURY
Mary E. Rinella, MD. — 010
EFFICACY AND SAFETY OF SUBCUTANEOUS SEMAGLUTIDE ONCE-DAILY VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
